173 related articles for article (PubMed ID: 15499599)
1. Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers.
Ranger GS; Jewell A; Thomas V; Mokbel K
J Surg Oncol; 2004 Nov; 88(2):100-3. PubMed ID: 15499599
[TBL] [Abstract][Full Text] [Related]
2. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Half E; Tang XM; Gwyn K; Sahin A; Wathen K; Sinicrope FA
Cancer Res; 2002 Mar; 62(6):1676-81. PubMed ID: 11912139
[TBL] [Abstract][Full Text] [Related]
3. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
Oliveira VM; Piato S; Silva MA
Breast Cancer Res Treat; 2006 Feb; 95(3):235-41. PubMed ID: 16322898
[TBL] [Abstract][Full Text] [Related]
4. Expression of cyclooxygenase-2 in malignant and benign breast tumors.
Watanabe O; Shimizu T; Imamura H; Kinoshita J; Utada Y; Okabe T; Kimura K; Hirano A; Yoshimatsu K; Aiba M; Ogawa K
Anticancer Res; 2003; 23(4):3215-21. PubMed ID: 12926055
[TBL] [Abstract][Full Text] [Related]
5. The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue.
Leo C; Faber S; Hentschel B; Höckel M; Horn LC
Ann Diagn Pathol; 2006 Dec; 10(6):327-32. PubMed ID: 17126249
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium.
Shim V; Gauthier ML; Sudilovsky D; Mantei K; Chew KL; Moore DH; Cha I; Tlsty TD; Esserman LJ
Cancer Res; 2003 May; 63(10):2347-50. PubMed ID: 12750248
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer.
Ristimäki A; Sivula A; Lundin J; Lundin M; Salminen T; Haglund C; Joensuu H; Isola J
Cancer Res; 2002 Feb; 62(3):632-5. PubMed ID: 11830510
[TBL] [Abstract][Full Text] [Related]
8. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
Perrone G; Santini D; Vincenzi B; Zagami M; La Cesa A; Bianchi A; Altomare V; Primavera A; Battista C; Vetrani A; Tonini G; Rabitti C
Histopathology; 2005 May; 46(5):561-8. PubMed ID: 15842638
[TBL] [Abstract][Full Text] [Related]
9. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer.
Sivula A; Talvensaari-Mattila A; Lundin J; Joensuu H; Haglund C; Ristimäki A; Turpeenniemi-Hujanen T
Breast Cancer Res Treat; 2005 Feb; 89(3):215-20. PubMed ID: 15754118
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome.
Vestey SB; Perks CM; Sen C; Calder CJ; Holly JM; Winters ZE
Breast Cancer Res; 2005; 7(1):R119-29. PubMed ID: 15642160
[TBL] [Abstract][Full Text] [Related]
11. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence.
Barnes N; Haywood P; Flint P; Knox WF; Bundred NJ
Br J Cancer; 2006 Jan; 94(2):253-8. PubMed ID: 16421596
[TBL] [Abstract][Full Text] [Related]
12. Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer.
Ranger GS; Thomas V; Jewell A; Mokbel K
Anticancer Res; 2004; 24(4):2349-51. PubMed ID: 15330183
[TBL] [Abstract][Full Text] [Related]
13. p38 regulates cyclooxygenase-2 in human mammary epithelial cells and is activated in premalignant tissue.
Gauthier ML; Pickering CR; Miller CJ; Fordyce CA; Chew KL; Berman HK; Tlsty TD
Cancer Res; 2005 Mar; 65(5):1792-9. PubMed ID: 15753376
[TBL] [Abstract][Full Text] [Related]
14. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.
Boland GP; Butt IS; Prasad R; Knox WF; Bundred NJ
Br J Cancer; 2004 Jan; 90(2):423-9. PubMed ID: 14735188
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study.
Çiriş IM; Bozkurt KK; Başpinar S; Kapucuoğlu FN
Pathol Res Pract; 2011 Mar; 207(3):182-7. PubMed ID: 21371829
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of cyclooxygenase-2 is associated with breast carcinoma and its poor prognostic factors.
Shim JY; An HJ; Lee YH; Kim SK; Lee KP; Lee KS
Mod Pathol; 2003 Dec; 16(12):1199-204. PubMed ID: 14681319
[TBL] [Abstract][Full Text] [Related]
17. [The clinical significance of expression of cyclooxygenase-2 gene in breast cancer].
Guo GL; Yao ZX; Wu J
Zhonghua Yi Xue Za Zhi; 2003 Oct; 83(19):1661-4. PubMed ID: 14642098
[TBL] [Abstract][Full Text] [Related]
18. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
19. Ductal carcinoma in situ of the breast and heparanase-1 expression: a molecular explanation for more aggressive subtypes.
Maxhimer JB; Pesce CE; Stewart RA; Gattuso P; Prinz RA; Xu X
J Am Coll Surg; 2005 Mar; 200(3):328-35. PubMed ID: 15737842
[TBL] [Abstract][Full Text] [Related]
20. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
